Fund+
Leuven, Belgium26
42M
19
2.89
6
0.27
3
- Areas of investment
Summary
This Fund+ works on 18 percentage points less the average amount of lead investments comparing to the other organizations. The real fund results show that this VC is 13 percentage points more often commits exit comparing to other companies. The fund is generally included in less than 2 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars. The top amount of exits for fund were in 2014. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity.
We also calculated 5 valuable employees in our database.
The typical case for the fund is to invest in rounds with 6-7 participants. Despite the Fund+, startups are often financed by Caixa Capital Risc, Shire, SFPI-FPIM. The meaningful sponsors for the fund in investment in the same round are S.R.I.W., V-Bio Ventures, SFPI-FPIM. In the next rounds fund is usually obtained by curative ventures, V-Bio Ventures, Shinsei Corporate Investment Limited.
The fund has specific favorite in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most successful fund investment fields, there are Pharmaceutical, Health Care. Among the various public portfolio startups of the fund, we may underline Minoryx Therapeutics, ITeos Therapeutics, Promethera Biosciences
Investor highlights
- Industry focus
- Stage focus
- Geo focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 26
- Lead investments
- 6
- Exits
- 3
- Rounds per year
- 2.89
- Follow on index
- 0.27
- Investments by industry
- Biotechnology (24)
- Health Care (13)
- Therapeutics (12)
- Medical (11)
- Pharmaceutical (10) Show 7 more
- Investments by region
- Belgium (13)
- Germany (3)
- United States (4)
- Spain (3)
- France (2) Show 1 more
- Peak activity year
- 2022
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 7
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Barosi | 01 Jan 2016 | Food and Beverage, Food Processing, Grocery, Nutrition, Organic Food, Fast-Moving Consumer Goods, Food Delivery, Farmers Market | Seed | Haryana, Gurgaon, India | |
| Kinemagic | 01 Oct 2019 | Software, Information Technology, Augmented Reality, Virtual Reality, GovTech, Industrial, Military | Seed | 3M | United States, Louisiana, Metairie |
| Novadip Biosciences | 28 Oct 2021 | Biotechnology, Health Care, Medical, Therapeutics | Early Stage Venture | 22M | Walloon Brabant, Belgium, Belgium |
| Tubulis | 14 Mar 2024 | Biotechnology, Health Care, Life Science, Pharmaceutical, Therapeutics | Early Stage Venture | 151M | Munich, Bavaria, Germany |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.